



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Risuteganib (trifluoroacetate salt)

Item No. 33303

Formal Name: glycyl-L-glycyl(sulfo)-D-alanyl-L-threonyl-L-proline, trifluoroacetate salt
Synonym: ALG-1001
MF: $C_{22}H_{39}N_9O_{11}S \cdot XCF_3COOH$
FW: 637.7
Purity: $\geq 95\%$
Supplied as: A crystalline solid
Storage: $-20^\circ C$
Stability: ≥ 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Risuteganib (trifluoroacetate salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the risuteganib (trifluoroacetate salt) in the solvent of choice, which should be purged with an inert gas. Risuteganib (trifluoroacetate salt) is soluble in DMSO.

Description

Risuteganib is an anti-integrin peptide and a derivative of RGD peptide (Item No. 14501).¹ Risuteganib (400 μM) protects against hydroquinone-induced necrosis and apoptosis, as well as inhibits hydroquinone-induced production of reactive oxygen species (ROS), in human retinal pigment epithelial (RPE) cells.² It decreases the expression of BAX, VEGFA, and ITB1 in human age-related macular degeneration (AMD) cybrid cell lines when used at a concentration of 20 mg/ml.³ Risuteganib arrests aberrant blood vessel growth mediated by $\alpha V\beta 3$, $\alpha V\beta 5$, and $\alpha 5\beta 1$ integrins *in vivo*.¹

References

1. Kaiser, P., Boyer, D.D., Campochiaro, P.A., *et al.* Integrin peptide therapy: The first wet AMD experience. *Invest. Opth. Vis. Sci.* **54**(15), 2177 (2013).
2. Yang, P., Shao, Z., Besley, N.A., *et al.* Risuteganib protects against hydroquinone-induced injury in human RPE cells. *Invest. Ophthalmol. Vis. Sci.* **61**(10), 35 (2020).
3. Schneider, K., Chwa, M., Atilano, S.R., *et al.* Differential effects of risuteganib and bevacizumab on AMD cybrid cells. *Exp. Eye Res.* **203**, 108287 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/09/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM